Neonatal monosodium glutamate treatment alters the response of median eminence luteinizing hormone-releasing hormone nerve terminals to potassium and prostaglandin E2.
D000818:Animals; D000831:Animals, Newborn; D015232:Dinoprostone; D005260:Female; D005971:Glutamates / Q000494:pharmacology*; D007987:Gonadotropin-Releasing Hormone / Q000378:metabolism*; D007030:Hypothalamo-Hypophyseal System / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D008473:Median Eminence / Q000187:drug effects / Q000378:metabolism*; D009474:Neurons / Q000502:physiology; D009929:Organ Size / Q000187:drug effects; D010477:Perfusion; D010903:Pituitary Gland, Anterior / Q000187:drug effects; D011188:Potassium / Q000494:pharmacology*; D011458:Prostaglandins E / Q000494:pharmacology*; D011467:Prostate / Q000187:drug effects; D051381:Rats; D012970:Sodium Glutamate / Q000494:pharmacology*; D013737:Testis / Q000187:drug effects
D005971:Glutamates; D011458:Prostaglandins E; D007987:Gonadotropin-Releasing Hormone; D015232:Dinoprostone; D011188:Potassium; D012970:Sodium Glutamate